Maria Castellanos Hugo MacDermott-Opeskin Jon Ainsley Pat Walters The ExpansionRx challenge, launched on October 27, 2025, closed two weeks ago! We are extremely grateful to everyone who participated and made this incredible learning experience possible for the ML and ADMET communities. After releasing the final leaderboard in our previous blogpost.
Maria Castellanos Hugo MacDermott-Opeskin Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties can make or break the preclinical and clinical development of small molecules. At OpenADMET we aim to address the unpredictable nature of these properties through open science, generating high-quality experimental data and building robust predictive models of ADMET
Authors: Devany West, Ph. D., Software Scientist, and Cynthia Xu, Research Software Engineer OpenADMET’s mission is to develop ADMET models for drug discovery Drug discovery is a risky venture: it is estimated that nearly 30% of all drug candidates fail due to safety concerns, and as many as 20%
Intermediate leaderboard release Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties can make or break the preclinical and clinical development of small molecules. At OpenADMET we address the unpredictable nature of these properties through open science, generating experimental data and building predictive models of ADMET properties. A key component of
Or, how do you know what you don't know? Author: Sean Colby, Data Scientist, OpenADMET Introduction At OpenADMET, we are chartered with providing data and models in support of screening molecules against anti-targets and other adverse ADMET (absorbtion, distribution, metabolism, excretion, toxicity) properties. As a motivating example, we
Additional details on the coming challenge Absorption, Distribution, Metabolism, Excretion and Toxicity–ADMET–properties can make or break preclinical and clinical development of small molecules. At OpenADMET we address the unpredictable nature of these properties through open science, generating experimental data and building predictive models of ADMET properties. A key
Small molecules continue to be the bricks and mortar of drug discovery globally, accounting for ~75% of FDA approvals over the last decade. Oral bioavailability, easily tunable properties, modulation of a wide range of mechanisms, and ease of manufacturing make small molecules highly attractive as therapeutic agents. Moreover, emerging small
Author: Pat Walters, Chief Scientist, OpenADMET Originally published on Practical Cheminformatics. Starting today, September 15, 2025, I will assume a new role as Chief Scientist at OpenADMET, an open science initiative that combines high-throughput experimentation, computation, and structural biology to enhance the understanding and prediction of absorption, distribution, metabolism, excretion,
Small molecule therapies have always been and continue to be the dominant way we treat diseases worldwide. Small molecules have unique advantages such as cost, scalability, convenience, the ability to get into every organ/cell and modulate a wide variety of targets/mechanisms – especially as compared to other modalities like